Wow,

You diminish the value of this board with your statement that "...Cardiogenics is doing as well as can be expected with no income coming with no thanks to Merck!" Cardiogenics' failure to execute its development program per its public statements is to blame for the share price not Merck.

If Cardiogenics had demonstrated the superiority of its silver coated beads and hand held Point of Care analyzer in the head-to-head study as it promised, then IMO the Cardiogenics' share price would be multiples of where it is today and sales of the beads would be establishing a meaningful revenue stream.

Ante